Clinical Trials
175 trialsMR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer
Medical College of Wisconsin
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
University of Alabama at Birmingham
PERSEVERE
Hoosier Cancer Research Network
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NRG Oncology
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Georgetown University
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
University of California, San Francisco
Sunitinib and Capecitabine for First Line Colon Cancer
Georgetown University
CEDAR
University of Oxford
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Case Comprehensive Cancer Center
OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Georgetown University
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
M.D. Anderson Cancer Center
PEARL
Spanish Breast Cancer Research Group
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
CHARIOT
University of Oxford
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Georgetown University
Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Herlev Hospital
CORRECT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
University of Southern California
Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer
M.D. Anderson Cancer Center
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
University of Nebraska
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
M.D. Anderson Cancer Center
OBELICS
National Cancer Institute, Naples
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
Spanish Breast Cancer Research Group
Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Memorial Sloan Kettering Cancer Center
Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo
Barbara Ann Karmanos Cancer Institute
Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer
Ludwig Institute for Cancer Research
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
TMZ-Cap
Weill Medical College of Cornell University
PazoX
GBG Forschungs GmbH
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
SCRI Development Innovations, LLC
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
University of Pittsburgh
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
SCRI Development Innovations, LLC
Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer
Loma Linda University
TreeTopp
ASLAN Pharmaceuticals